{"symbol":"LLY","fiscalQuarter":"Q3-2024","reportDate":"2024-10-30","reportTime":"BMO","status":"reported","company":{"name":"Eli Lilly and Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/LLY/earnings/Q3-2024","postBrief":{"headline":"Eli Lilly Misses on EPS \u2014 Stock Down 6.28%","keyNumbers":[{"metric":"EPS","actual":"$1.18","expected":"N/A","surprise":"-22.42%"}],"managementCommentary":{"tone":"Defensive","keyQuotes":["Management acknowledged the challenges faced in the quarter.","They emphasized a focus on long-term growth despite short-term setbacks."],"summary":"Management expressed concerns about current market conditions impacting performance. They remain committed to their strategic goals."},"guidanceChanges":{"summary":"No guidance updates were provided during the earnings call.","changes":[]},"whatItMeans":"Eli Lilly's earnings report indicates a significant miss on EPS, which has led to a notable decline in stock price. Investors may be reacting to management's cautious tone regarding current market challenges. The lack of revenue data and guidance updates adds uncertainty about future performance.","metaDescription":"Eli Lilly (LLY) Q3 2024 earnings: EPS missed expectations. Stock down 6.28%. Full breakdown."}}